Toni Choueiri and Patrick Ott describe how this peptide-based vaccine was peronalized to dozens of the patient's neoantigens in this this ad

He talks about todays M&A heavy news and the market reaction to it, and comments on Xenon, Madrigal, Nurix, and Wave.

He shares his thoughts on Moderna's transition, what policies he would like to see promoted in government, competing with China, and the...

He discusses news from Biogen and Regeneron, and shares his top picks Xenon, Soleno, and Lexeo.

He provides a 2024 year-end recap and 2025 outlook DOWNLOAD THE FULL REPORT #Sponsored

Jack Allen discusses data that Arcellx and Vor had at last week's ASH annual meeting, and discusses Mereo, Ultragenyx, Instil Bio, Taysha...

He discusses the founding of Dimension, and highlights entrepreneurs and portfolio companies that have matched the firm's focused...

Over 600 people registered for the event and took in company presentations and networking on the floor of the NYSE.

He talks modalities and targets, and comments on Arcellx, Galapagos, BeiGene, Nurix, Kura, JNJ, Syndax, AbbVie AstraZeneca, CellCentric,...

Fresh off of raising more than €2 billion for two new funds in October, he gives his take on the biotech markets both in Europe and...

KoreaBIO Vice President Seung-Kyou Lee and Director of International & Public Affairs Jurie Hwang describe the enormous growth the sector...

He discusses the latest in TILs, cell therapy, multispecifics, oncolytic viruses and more.

From the largest conference for life sciences in Texas each year, she describes the significant growth in infrastructure, startups,...

He says there has been an upswing in investors looking at companies. Plus, his thoughts on BioInvent, Oculis, and Camurus. Brought to you by

She discusses building systems around early diagnostics and treatment, rare disease discovery, mitochondrial disease and the brain,...

Ted Fjällman covers the history of the firm, and rationale for going public this year. Plus, he highlights portfolio companies such as...

Cait Brumme highlights MassChallenge's equity-free model and how it helps biotech entrepreneurs from the earliest stages to understanding...

Having been involved with Reata, Taysha Gene Therapies (founder), ReCode Therapeutics and more, RA has a good handle on the biotech scene...

Nicole Small discusses events that have recently taken place like the acquisition of Reata, ARPA-H choosing Dallas for a regional center,...

Dr. Scherer describes the work he is doing in areas like diabetes and fibro-inflammation. Plus, PriveBio's programs focusing on...